GlassScriptPhysician profile
Bita A Ghaffari
NPI 1568423697
$487.89
in general payments reported to CMS, 2019-2025
14 companies · $66.61 in 2025
The $66.61 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.09 · 2020: $14.60 · 2021: $99.34 · 2022: $53.18 · 2023: $115 · 2024: $70.48 · 2025: $66.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $251.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $106.25 | 2022-2024 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $59.23 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $52.33 | 2021 | |
| Sunovion Pharmaceuticals INC. | $45.27 | 2019 | |
| Novo Nordisk INC | $43.84 | 2023 | Rybelsus, Ozempic |
| Abbvie INC. | $38.74 | 2021-2025 | |
| Amgen INC. | $34.78 | 2023-2025 | Evenity, Prolia |
| Exact Sciences Corporation | $19.72 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $19.13 | 2021 | |
| Glaxosmithkline, LLC. | $15.50 | 2024 | Trelegy Ellipta |
| Exelixis INC. | $14.68 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.60 | 2020 | |
| Genzyme Corporation | $12.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bita Ghaffari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.